Everolimus (RAD001) in Breast Cancer—The BOLERO Program
What is the BOLERO clinical trial program? Novartis has initiated the BOLERO (Breast cancer trials of OraLEveROlimus) clinical trial program to evaluate everolimus in locally advanced or metastatic breast cancer.
Currently, the BOLERO program comprises:
BOLERO-3 (To find out more about this breast cancer clinical trial, click here)
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
Disclaimer : This is a global web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.
BOLERO-3 (To find out more about this breast cancer clinical trial,